DOCSLIB.ORG

Master Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Master Drug List NBEO Drug List (SORTED BY TRADE NAME WITH GENERIC EQUIVALENT) Abilify aripiprazole Atarax hydroxyzine Absorica isotretinoin Ativan lorazepam Accolate zafirlukast Atripla efavirenz, emtricitabine, tenofovir Accupril quinapril Atrovent ipratropium Achromycin tetracycline Augmentin amoxicillin-clavulanate Aciphex rabeprazole Avagard chlorhexidine gluconate 1% and Actos pioglitazone ethyl alcohol 61% Avandia rosiglitazone Acular ketorolac Avastin bevacizumab Acuvail ketorolac Azasan azathioprine Advair fluticasone propionate AzaSite azithromycin Advil ibuprofen Avodart dutasteride AeroBid flunisolide Azopt brinzolamide Afrin oxymetazoline Bactrim trimethoprim-sulfamethoxazole Aggrenox aspirin and dipyridamole Bactrim DS trimethoprim-sulfamethoxazole Alamast pemirolast Bactroban mupirocin Alaway ketotifen Baquacil polyhexamethylene biguanide Albalon naphazoline Beconase AQ beclomethasone Albenza albendazole Benadryl diphenhydramine Alcaine proparacaine Bepreve bepotastine Aldactone spironolactone Besivance besifloxacin Aleve naproxen Betadine povidone-iodine Allegra fexofenadine Betagan levobunolol Allegra-D fexofenadine-pseudoephedrine Betasept chlorhexidine topical Alluvia lopinavir Betaseron interferon beta-1b Alocril nedocromil Betimol timolol Alomide lodoxamide Betoptic S betaxolol Alphagan P brimonidine Biopatch chlorhexidine topical Alrex loteprednol 0.2% Blephamide sulfacetamide-prednisolone Ambien zolpidem Bleph-10 sulfacetamide Amicar aminocaproic acid Bloxiverz neostigmine Amikin amikacin Botox onabotulinumtoxinA Amoxil amoxicillin Brolene propamidine isethionate Amphocin amphotericin B Bromday bromfenac Amrix cyclobenzaprine Calamine zinc oxide and iron oxide Anectine succinylcholine Calan verapamil Ansaid flurbiprofen Calgon Vesta chlorhexidine topical Antivert meclizine Capoten captopril Apresoline hydralazine Carafate sucralfate Aralen chloroquine Carbocaine mepivacaine HCl injection Aricept donepezil Cardizem diltiazem Aristocort triamcinolone The listed trade names do not include the ® mark; however, all trade names are registered by their respective pharmaceutical companies. NBEO Drug List (SORTED BY TRADE NAME WITH GENERIC EQUIVALENT) Cardura doxazosin Depakote divalproex Catapres clonidine Depo-Provera medroxyprogesterone Catarase chymotrypsin Detrol tolterodine tartrate Ceftin cefuroxime Detrol LA tolterodine tartrate extended Celebrex celecoxib release Dexedrine dextroamphetamine Celexa citalopram hydrobromide Dexilant dexlansoprazole Celluvisc carboxymethylcellulose Diabeta glyburide ChloraPrep One- chlorhexidine topical Step Diabinese chlorpropamide Chlor-Trimeton chlorpheniramine Diamox acetazolamide Cialis tadalafil Diamox Sequels acetazolamide XR Ciloxan ciprofloxacin (ophthalmic) Diflucan fluconazole Cipro ciprofloxacin (systemic) Dilantin phenytoin Clarinex desloratadine Dimetane brompheniramine Claritin loratadine Diovan valsartan Claritin-D loratadine-pseudoephedrine Dispermox amoxicillin Cleocin clindamycin Diuril chlorothiazide Cliradex tea tree oil Dolophine methadone Combigan brimonidine-timolol Doryx doxycycline Combivent ipratropium bromide-albuterol Dulcolax docusate sodium Respimat Duranest-MPF etidocaine Compazine prochlorperazine Durezol difluprednate Compro prochlorperazine Dyazide hydrochlorothiazide-triamterene Cordarone amiodarone Dynacin minocycline Coreg carvedilol Dyna-Hex chlorhexidine topical Cortef hydrocortisone Dyrenium triamterene Cosopt dorzolamide-timolol Effexor venlafaxine Coumadin warfarin Efudex fluorouracil Cozaar losartan Elavil amitriptyline Crestor rosuvastatin Elestat epinastine Crolom cromolyn sodium Eliquis apixaban Cuprimine penicillamine Emadine emedastine Cyclogyl cyclopentolate Epipen epinephrine Cymbalta duloxetine hydrochloride Epivir-HBV lamivudine Cytotec misoprostol Ergomar ergotamine Cytovene ganciclovir Eulexin flutamide Danazol danocrine Evista raloxifen Daranide dichlorphenamide Eylea aflibercept Daraprim pyrimethamine Feldene piroxicam Darvocet propoxyphene-aspirin Flagyl metronidazole (oral) Darvon propoxyphene Flomax tamsulosin Demerol meperidine The listed trade names do not include the ® mark; however, all trade names are registered by their respective pharmaceutical companies. NBEO Drug List (SORTED BY TRADE NAME WITH GENERIC EQUIVALENT) Flonase fluticasone Isuprel isoproterenol Floropryl isoflurophate Jetrea ocriplasmin Flovent fluticasone Kaletra lopinavir FML fluorometholone K-Dur potassium chloride Folixor folinic acid Keflex cephalexin Foradil formoterol fumarate Kenalog triamcinolone (injectable) Fortaz ceftazidime Klonopin clonazepam Fosamax alendronate Klor-Com potassium chloride Foscavir foscarnet Kwell gamma-hexachlorocyclohexane FreshKote polyvinyl pyrrolidone Lacri-Lube paraffin-mineral oil Gantanol sulfamethoxazole Lanoxin digoxin Gantrisin sulfisoxazole Lasix furosemide Garamycin gentamicin Lastacaft alcaftadine Genoptic gentamicin Lescol fluvastatin Gilenya fingolimod Levaquin levofloxacin (oral) Glucophage metformin Levitra vardenafil Glucotrol glipizide Levothroid levothyroxine Gocovri amantadine Lexapro escitalopram Grifulvin V griseofulvin Lipitor atorvastatin Haldol Decanoate haloperidol Lodine etodolac Hibiclens chlorhexidine topical Lopid gemfibrozil Hibistat Towelette chlorhexidine topical Lopressor metoprolol Horizant gabapentin Lopressor HCT metoprolol-hydrochlorothiazide Hydrodiural hydrochlorothiazide Lortab acetaminophen-hydrocodone Hydrodiuril hydrochlorothiazide Lotemax loteprednol 0.5% Hysingla ER hydrocodone Lotensin benazepril Hytrin terazosin Lovaza omega-3-acid ethyl esters Ilotycin erythromycin Lucentis ranibizumab Imdur isosorbide mononitrate Lumigan bimatoprost Imitrex sumatriptan Lunesta eszopiclone Imuran azathioprine Lupron leuprolide Inderal propranolol Luvox fluvoxamine Indocin indomethacin Lyrica pregabalin Intron A alfa-2b interferon Macugen pegaptanib Invokana canagliflozin MacuHealth eye vitamins Iopidine apraclonidine Marcaine bupivacaine Iquix levofloxacin (ophthalmic) Marcaine Epi bupivacaine with epinephrine Ismelin guanethidine Maxidex dexamethasone Isoptin verapamil Maxipime cefepime IsoptoCarpine pilocarpine Maxitrol neomycin-polymyxin B- dexamethasone Isordil isosorbide The listed trade names do not include the ® mark; however, all trade names are registered by their respective pharmaceutical companies. NBEO Drug List (SORTED BY TRADE NAME WITH GENERIC EQUIVALENT) Maxzide hydrochlorothiazide Nevanac nepafenac Medrol Dosepak methylprednisolone Nexium esomeprazole Mellaril thioridazine Niaspan nicotinic acid extended release Mestinon pyridostigmine Nitrobid nitroglycerin (topical) MetroCream metronidazole (topical) Nitrostat nitroglycerin (sublingual) MetroGel metronidazole (topical) Nizoral ketoconazole Mevacor lovastatin Nolvadex tamoxifen Micro-K potassium chloride Noroxin norfloxacin Micronase glyburide Norvasc amlodipine Microsulfan sulfadiazine Novolin 70/30 insulin isophane/insulin regular Microzide hydrochlorothiazide Nydrazid isoniazid Minipress prazosin Occlusal salicylic acid Minocin minocycline Ocufen flurbiprofen Miostat carbachol Ocuflox ofloxacin MiraLax polyethylene glycol Ocupress carteolol Monistat IV miconazole Ocuvite eye vitamins Monistat-Derm miconazole PreserVision Oleptro trazodone Motrin ibuprofen Opticrom cromolyn sodium Moxeza moxifloxacin OptiPranolol metipranolol Mucinex guaifenesin Optivar azelastine Mucomyst acetylcysteine Oretic hydrochlorothiazide Muro 128 sodium chloride Orinase tolbutamide Mutamycin mitomycin Ortho Tri-Cyclen norgestimate-ethinyl estradiol Myambutol ethambutol Ortho-Novum norethindrone-ethinyl estradiol Mycelex clotrimazole OS-CAL calcium carbonate Mycostatin nystatin Osmitrol mannitol Mydriacyl tropicamide Oxycontin oxycodone Naphcon-A naphazoline-pheniramine Pacerone amiodarone Naprosyn naproxen Parlodel bromocriptine Narcan naloxone Pataday olopatadine Nardil phenelzine Patanol olopatadine Nasacort AQ triamcinolone (topical) Paxil paroxetine Nasarel flunisolide Pazeo olopatadine Natacyn natamycin Pegasys peginterferon alfa-2a Neosporin polymyxin B-bacitracin-neomycin (ointment) Peg-Intron peginterferon alfa-2b Neosporin polymyxin B-neomycin-gramicidin Pepcid famotidine (suspension) Persantine dipyridamole Neo-Synephrine phenylephrine Phenergan promethazine Nephrocaps dialysis vitamins Pilocar pilocarpine Neptazane methazolamide Plaquenil hydroxychloroquine Neurontin gabapentin The listed trade names do not include the ® mark; however, all trade names are registered by their respective pharmaceutical companies. NBEO Drug List (SORTED BY TRADE NAME WITH GENERIC EQUIVALENT) Plavix clopidogrel Ritalin methylphenidate Plendil felodipine Rocephin ceftriaxone Pletal cilostazol Sandimmune cyclosporine Polyhexanide polyhexamethylene biguanide Scrub Care chlorhexidine topical (PHMB) Exidine Polysporin polymyxin B-bacitracin Sensorcaine bupivacaine Polytrim trimethoprim-polymyxin B Sensorcaine with bupivacaine with epinephrine Pravachol pravastatin epinephrine Serevent salmeterol Pred Forte prednisolone acetate 1% Pred Mild prednisolone acetate 0.125% Simbrinza brinzolamide-brimonidine Premarin estrogen Sinemet carbidopa-levodopa Singulair montelukast Prevacid lansoprazole Slo-Niacin niacin, nicotinic acid Prilosec omeprazole Solu-Medrol methylprednisolone Primsol trimethoprim Spiriva tiotropium Prinivil lisinopril Prinzide HCTZ-lisinopril Spectrum-4 chlorhexidine topical Procardia nifedipine Sudafed pseudoephedrine Sumycin tetracycline Procomp prochlorperazine Sustiva efavirenz Prograf tacrolimus Symbicort budesonide/formoterol Prolensa bromfenac
Load more

Recommended publications
  • 2019 Aetna Pharmacy Drug Guide Aetna Premier Plus Plan
    Plan for your best health 2019 Aetna Pharmacy Drug Guide Aetna Premier Plus Plan aetna.com 05.02.414.1 O (12/19) Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna). Aetna Pharmacy Management refers to an internal business unit of Aetna Health Management, LLC. Aetna Pharmacy Management administers, but does not offer, insure or otherwise underwrite the prescription drug benefits portion of your health plan and has no financial responsibility therefor. 2019 Aetna Commercial Plan (Premier Plus) Table of Contents INFORMATIONAL SECTION..................................................................................................................7 *5-HT4 RECEPTOR AGONISTS*** - DRUGS FOR THE STOMACH................................................ 18 *ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS* - DRUGS FOR THE NERVOUS SYSTEM.................................................................................................................................18 *AGENTS FOR NARCOTIC WITHDRAWAL*** - DRUGS FOR ADDICTION............................... 22 *AGENTS FOR OPIOID WITHDRAWAL*** - DRUGS FOR ADDICTION......................................22 *AMEBICIDES* - DRUGS FOR INFECTIONS.....................................................................................22 *AMINO ACIDS*** - DRUGS FOR NUTRITION................................................................................ 22 *AMINOGLYCOSIDES* - DRUGS FOR
    [Show full text]
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Intraocular Pressure Rise After Phacoemulsification Prophylactic
    British Journal of Ophthalmology 1995; 79: 809-813 809 Intraocular pressure rise after phacoemulsification Br J Ophthalmol: first published as 10.1136/bjo.79.9.809 on 1 September 1995. Downloaded from with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience Thomas G Bomer, Wolf-Dietrich A Lagreze, Jens Funk Abstract pressure rises usually occur between 6 and 8 Aims-A prospective clinical trial was hours after surgery.6 carried out to evaluate the effect of Various antiglaucomatous agents have been prophylactic medication, the technique of used to prevent the intraocular pressure rise wound closure, and the surgeon's experi- after cataract extraction. Oral acetazolamide15 16 ence on the intraocular pressure rise after and topical timolol'6-19 lowered the pressure cataract extraction. rise in the early period after intracapsular and Methods-In 100 eyes, the intraocular extracapsular cataract extraction. Levobunolol pressure was measured before as well as proved to be superior to timolol 4-7 hours 2-4, 5-7, and 22-24 hours after phaco- after extracapsular cataract extraction.20 Apra- emulsification and posterior chamber lens clonidine lowered the intraocular pressure rise implantation. Each of 25 patients received after uncomplicated phacoemulsification21 and either 1% topical apraclonidine, 0.5%/o extracapsular cataract extraction22 23 when topical levobunolol, 500 mg oral acetazo- given 30 minutes to 1 hour before surgery, lamide, or placebo. Forty four eyes were whereas immediate postoperative treatment operated with sclerocorneal sutureless with apraclonidine was ineffective.22 24 Miotics tunnel and 56 eyes with corneoscleral are frequently used to promote miosis and incision and suture.
    [Show full text]
  • Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients with Pseudophakia and Aphakia a 6-Month Randomized Trial
    CLINICAL SCIENCES Blood-Aqueous Barrier Changes After the Use of Prostaglandin Analogues in Patients With Pseudophakia and Aphakia A 6-Month Randomized Trial Enyr S. Arcieri, MD; Alessandro Santana, MD; Fabiano N. Rocha, MD; Gustavo L. Guapo, MD; Vital P. Costa, MD Objectives: To investigate the effects of prostaglandin throughout follow-up (P Ͻ .02). Four latanoprost- analogues on the blood-aqueous barrier and to evaluate treated eyes, 1 bimatoprost-treated eye, and 1 travoprost- the occurrence of cystoid macular edema in aphakic or treated eye developed cystoid macular edema; all cases pseudophakic patients with glaucoma. resolved after discontinuation of the prostaglandin ana- logue and treatment with topical diclofenac sodium. Mean Methods: In this randomized, masked-observer, 6-month intraocular pressure reductions after 6 months were higher clinical trial, patients with primary open-angle, pseudo- for the latanoprost (26%), bimatoprost (28%), and tra- phakic, or aphakic glaucoma were treated once daily with voprost (29%) groups than for the control (3%) and uno- bimatoprost (n=16), latanoprost (n=15), or travoprost prostone (14%) groups (PϽ.05). Bimatoprost induced (n=17) or twice daily with unoprostone (n=16) or lu- significantly higher hyperemia scores than latanoprost, bricant drops (control group) (n=16). Blood-aqueous bar- unoprostone, and placebo (PϽ.01). rier status, which was assessed using a laser flare meter; intraocular pressure; the occurrence of angiographic cys- toid macular edema; and conjunctival hyperemia were Conclusion: Bimatoprost, latanoprost, and travoprost use evaluated. may lead to disruption of the blood-aqueous barrier in patients with pseudophakia and aphakia. Results: Mean flare values were significantly higher in the bimatoprost, latanoprost, and travoprost groups Arch Ophthalmol.
    [Show full text]
  • Opioid and Other Substance Use Disorders
    OPIOID AND OTHER SUBSTANCE USE DISODERS Dr Amit Arya Additional Professor Department of Psychiatry KGMU Lucknow What are addictive substances? Any substance which when taken has an ability to change the person’s consciousness, thinking, mood, behaviour and motor functions Leading to take the substance repeatedly (World Health Organisation, 1992) …Also called as psychoactive substances Layman term: “Drugs” Why are certain substances addictive? Intake of any substance – oral, inhalational, injecting Enters the bloodstream Acts on a specific body part, such as heart, lung, stomach, etc. Addictive substances act on brain Addictive Substances act on brain All substances acting on the brain are not addictive Addictive substances I want to primarily act on a particular take that area/group of neurons in the drug again! brain, Leading the individual to repeatedly administer the addictive / psychoactive substance → “drug seeking” behaviour Addictive substances primarily act on a particular area/group of neurons in the brain. Regions controlling emotions, thinking, Frontal region judgement & memory Mid Brain How are addictive substances different from each other? Broad actions Chemical that the drug class of drugs produces on the brain Source of drug Natural/semi- TYPOLOGY synthetic/synthetic Mode of intake Oral/inhalational/ Availability – parenteral legal/illegal? (injections) Typology – Chemical Class Opioids Alcohol Cannabis Volatile solvents Based on chemical class Stimulants Tobacco Sedative- hypnotics Hallucinogens The usual drug-use
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management
    Journal of Clinical Medicine Review Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management Robert S. Jones Division of Pediatric Dentistry, Department of Developmental & Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] Abstract: Alpha-adrenergic agonists, such as the Imidazoline derivatives (ImDs) of oxymetazoline and xylometazoline, are highly effective hemostatic agents. ImDs have not been widely used in dentistry but their use in medicine, specifically in ophthalmology and otolaryngology, warrants consideration for pulpal hemostasis. This review presents dental healthcare professionals with an overview of ImDs in medicine. ImD solutions have the potential to be more effective and biocompatible than existing topical hemostatic compounds in pulpal management. Through a comprehensive analysis of the pharmacology of ImDs and the microphysiology of hemostasis regulation in oral tissues, a conceptual model of pulpal management by ImD solutions is presented. Keywords: hemostasis; alpha-adrenergic agonists; imidazoline; oxymetazoline; nasal; dental pulp; mucosa; apexogenesis; pulpotomy; direct pulp cap; dentistry 1. Overview Citation: Jones, R.S. Conceptual The purpose of this review is to formulate a conceptual model on the potential man- Model for Using Imidazoline agement of pulpal tissue by imidazoline derivatives (ImDs) based on a review of the Derivative Solutions in Pulpal literature that examines the hemostatic properties and mechanistic actions of these com- Management. J. Clin. Med. 2021, 10, 1212. https://doi.org/10.3390/ pounds in other human tissues. Commercial ImDs are formulated in solution with an- jcm10061212 timicrobial preservatives in order to act as ‘parenteral topical agents’ and used to manage ophthalmic inflammation, nasal congestion, and to control bleeding during otolaryngology Academic Editor: Rosalia surgery [1,2].
    [Show full text]
  • Transient Mydriasis Due to Opcon-A
    Open Access Austin Journal of Clinical Ophthalmology Special Article - Ophthalmology: Clinical Cases and Images Transient Mydriasis Due to Opcon-A Hava Donmez Keklikoglu1, Aubrey Gilbert2 and Nurhan Torun3* Abstract 1Department of Neurology, Ataturk Education and Opcon-A (pheniramine maleate/ naphazoline hydrochloride) is a topical Research Hospital, Turkey decongestant and antihistamine combination that is used to treat ocular allergies. 2Department of Ophthalmology, Massachusetts Eye and It is sold as an over the counter eye drop and is generally associated with very Ear Infirmary, USA few side effects. It may, however, cause mydriasis in some patients, though this 3Division of Ophthalmology, Department of Surgery, Beth is not a well-recognized occurrence. We present three cases in which transient Israel Deaconess Medical Center, USA mydriasis was attributed to Opcon-A use and emphasize consideration of this *Corresponding author: Nurhan Torun, Division drug in the differential diagnosis of temporary pupillary dilation. of Ophthalmology, Department of Surgery, Beth Israel Keywords: Transient mydriasis; Anisocoria; Naphazoline; Pheniramine; Deaconess Medical Center, 330 Brookline Avenue, Opcon-A Boston, MA 02215, USA Received: April 30, 2015; Accepted: May 04, 2015; Published: May 06, 2015 Case Reports the eye. Based on this history and his normal exam he was diagnosed with pharmacological mydriasis. He was advised not to use Opcon-A Case 1 and his pupillary dilation did not recur. A 29-year-old man was seen in Ophthalmology Clinic for a dilated left pupil which he had noted a few hours earlier on the day Case 3 of presentation. He had no other acute complaints. His past medical A 24-year-old woman was seen in Ophthalmology Clinic for history was notable for asthma for which he occasionally used an three separate episodes of transient right pupillary dilation lasting a inhaler.
    [Show full text]
  • Effect of Polyhexamethylene Biguanide in Combination with Undecylenamidopropyl Betaine Or Pslg on Biofilm Clearance
    International Journal of Molecular Sciences Article Effect of Polyhexamethylene Biguanide in Combination with Undecylenamidopropyl Betaine or PslG on Biofilm Clearance Yaqian Zheng 1,2,†, Di Wang 1,† and Luyan Z. Ma 1,3,* 1 State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; [email protected] (Y.Z.); [email protected] (D.W.) 2 College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China 3 Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China * Correspondence: [email protected]; Tel.: +86-10-64807437 † These authors have contributed equally to this work. Abstract: Hospital-acquired infection is a great challenge for clinical treatment due to pathogens’ biofilm formation and their antibiotic resistance. Here, we investigate the effect of antiseptic agent polyhexamethylene biguanide (PHMB) and undecylenamidopropyl betaine (UB) against biofilms of four pathogens that are often found in hospitals, including Gram-negative bacteria Pseudomonas aeruginosa and Escherichia coli, Gram-positive bacteria Staphylococcus aureus, and pathogenic fungus, Candida albicans. We show that 0.02% PHMB, which is 10-fold lower than the concentration of commercial products, has a strong inhibitory effect on the growth, initial attachment, and biofilm formation of all tested pathogens. PHMB can also disrupt the preformed biofilms of these pathogens. In contrast, 0.1% UB exhibits a mild inhibitory effect on biofilm formation of the four pathogens. This concentration inhibits the growth of S. aureus and C. albicans yet has no growth effect on P. aeruginosa or E. coli. UB only slightly enhances the anti-biofilm efficacy of PHMB on P.
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • New York State Medicaid Drug Utilization Board Meeting Agenda
    New York State Medicaid Drug Utilization Board Meeting Agenda The Drug Utilization (DUR) Board will meet April 24, 2014, from 9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York Agenda Items Preferred Drug Program (PDP) The DUR Board will review therapeutic classes, described and listed below, as they pertain to the PDP. The therapeutic classes to be reviewed contain new relevant clinical and/or financial information. Therapeutic classes not included on this agenda may be reviewed at a later date. The Board will review new clinical and financial information as required, to recommend preferred and non-preferred drugs. ^ The Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged. Those wishing to submit new clinical information must do so in an electronic format by April 9, 2014 or the Board may not have ample time to review the information. ^ The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf
    [Show full text]